Lupin launches fixed-dose triple combination inhaler for COPD in India
Benchmarks Nifty22,888.95-257.21FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.8 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.64 % Invest NowEnter search…
Lupin Ltd has launched Formoflo-G MDI, a new inhaler for chronic obstructive pulmonary disease management in India. This fixed-dose inhaler combines three therapies into a single device for better treatment outcomes. It aims to benefit over 55 million people living with COPD across the country. The Drug Controller General of India has approved this innovative product for use. Lupin is currently ranked second in the respiratory therapy segment in India.
Listen to this article in summarized format
Loading...×New Delhi: Drug maker Lupin Ltd on Tuesday announced the launch of Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler (MDI) for the management of chronic obstructive pulmonary disease (COPD) in India.The launch follows approval from the Drug Controller General of India (DCGI), the company said in a statement.
Formoflo-G MDI combines three established therapies- Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate-into a single inhaler for the long-term management and treatment of moderate to severe COPD. The product, which the company said is the world's first, is available as a twice-daily, single-strength fixed dose.
According to the company, the therapy aims to serve more than 55 million people living with COPD in India, where the condition remains a leading cause of death and disability.
"As respiratory diseases continue to impact millions across India, access to effective therapies remains critical... By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases," Lupin Managing Director Nilesh Gupta said.
Live Events
Rajeev Sibal, President - India Region Formulations at Lupin, noted that the product marks an important addition to the company's respiratory portfolio by bringing three therapies together in a single inhaler.
Citing IQVIA MAT March 2026 data, Lupin stated that it is currently ranked second in the respiratory therapy segment in India.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onchronic obstructive pulmonary disease (COPD)LupinIndiarespiratory diseasesGlycopyrronium BromideFormoterol FumarateFluticasone Propionaterespiratory therapy segment
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onchronic obstructive pulmonary disease (COPD)LupinIndiarespiratory diseasesGlycopyrronium BromideFormoterol FumarateFluticasone Propionaterespiratory therapy segment
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessStories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
